$KLRS News

Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer

Kalaris Therapeutics Appoints Liisa Bayko CFO

Why Is Kalaris Therapeutics Stock Gaining Friday?

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Kalaris Therapeutics To Present Additional Data From Phase 1a Single Ascending Dose Trial Of TH103 In Neovascular Age-Related Macular Degeneration At ASRS Annual Meeting; On Track To Share Initial Data From Phase 1b/2 Study In H1 Of 2027

Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board

Kalaris Appoints Laurie Keating to Board of Directors

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

TD Cowen Initiates Coverage On Kalaris Therapeutics with Buy Rating

Kalaris to Present at Clinical Trials at the Summit 2026

Wedbush Initiates Coverage On Kalaris Therapeutics with Outperform Rating, Announces Price Target of $17

Citizens Maintains Market Outperform on Kalaris Therapeutics, Lowers Price Target to $25

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Kalaris Therapeutics Q1 EPS $(0.46) Beats $(0.53) Estimate

Kalaris Therapeutics shares are trading higher after Morgan Stanley initiated its coverage on the stock with an Overweight rating and announced a price target of $14.

Kalaris Therapeutics shares are trading higher after Morgan Stanley initiated its coverage on the stock with an Overweight rating and announced a price target of $14.

Morgan Stanley Initiates Coverage On Kalaris Therapeutics with Overweight Rating, Announces Price Target of $14

Kalaris Therapeutics Launches Up To $100M At-The-Market Stock Offering Agreement With TD Cowen

Kalaris Therapeutics CFO Matthew Gall Resigns, Effective April 14

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates